文献速递慢阻肺

气道黏蛋白MUC5AC与MUC5B浓度与慢阻肺发生及进展:SPIROMICS队列分析

Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.
PubMed 文献 · Lancet Respir Med · 2021-05-28

本研究基于美国多中心SPIROMICS队列,对331名受试者(健康从不吸烟者、有风险戒烟者、慢阻肺患者)的诱导痰进行稳定同位素标记质谱定量MUC5AC和MUC5B。结果显示,MUC5AC浓度升高与慢阻肺表现(FEV1下降、FEF25-75%降低、急性加重频率增加、RV/TLC及PRM-fSAD升高、CAT评分增加)更可靠相关,且对吸烟暴露更敏感;

要点

  • MUC5AC较MUC5B与慢阻肺临床及影像学表现更相关。
  • 基线MUC5AC高浓度预测3年内肺功能下降和急性加重风险。
  • MUC5AC可能成为慢阻肺预后生物标志物及治疗靶点。

核心结论

  • 气道MUC5AC浓度升高可能参与慢阻肺的发生、进展、急性加重风险及整体发病机制。
  • MUC5AC浓度似乎是检测有风险个体及慢阻肺前期的客观生物标志物。
  • 产生MUC5AC的通路可能是未来治疗策略的潜在靶点。

研究设计与样本

  • SPIROMICS为多中心观察性研究,在美国6个临床中心及额外子站点招募40-80岁患者。
  • 本分析纳入331名参与者,包括40名健康从不吸烟者、90名有风险戒烟者和201名慢阻肺戒烟者。
  • 通过稳定同位素标记质谱法对诱导痰样本中的MUC5AC和MUC5B进行定量。

主要发现

  • MUC5AC浓度升高较MUC5B更可靠地与FEV1和FEF25-75%降低、前瞻性急性加重频率增加、RV/TLC和PRM-fSAD升高及CAT评分增加相关。
  • MUC5AC浓度对香烟烟雾暴露的反应性高于MUC5B。
  • 基线MUC5AC(而非MUC5B)浓度升高是3年随访期间FEV1、FEV1/FVC、FEF25-75%和CAT评分下降的显著预测因子。
  • 有风险组中当前吸烟者初次访视时MUC5AC浓度升高且3年内肺功能下降,而戒烟者初次访视时MUC5AC浓度正常且3年内肺功能保持。

临床怎么用

  • MUC5AC浓度可作为慢阻肺预后评估及治疗效果测试的新型生物标志物。
  • 针对MUC5AC产生通路的干预可能成为未来慢阻肺治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We previously described the contributions of increased total airway mucin concentrations to the pathogenesis and diagnosis of the chronic bronchitic component of chronic obstructive pulmonary disease (COPD). Here, we investigated the relative contribution of each of the major airway gel-forming mucins, MUC5AC and MUC5B, to the initiation, progression, and early diagnosis of airways disease in COPD. METHODS: SPIROMICS was a multicentre, observational study in patients aged 40-80 years recruited from six clinical sites and additional subsites in the USA. In this analysis, MUC5AC and MUC5B were quantitated by stable isotope-labelled mass spectrometry in induced sputum samples from healthy never-smokers, ever-smokers at risk for COPD, and ever-smokers with COPD. Participants were extensively characterised using results from questionnaires, such as the COPD assessment test (CAT) and St George's Respiratory Questionnaire; quantitative CT, such as residual volume/total lung capacity ratio (RV/TLC) and parametric response mapping-functional small airway disease (PRM-fSAD); and pulmonary function tests, such as FEV1, forced vital capacity (FVC), and forced expiratory flow, midexpiratory phase (FEF25-75%). Absolute concentrations of both MUC5AC and MUC5B were related to cross-sectional (baseline, initial visit) and 3-year follow-up longitudinal data, including lung function, small airways obstruction, prospective acute exacerbations, and smoking status as primary outcomes. This study is registered with ClinicalTrials.gov (NCT01969344). FINDINGS: This analysis included 331 participants (mean age 63 years [SEM 9·40]), of whom 40 were healthy never-smokers, 90 were at-risk ever-smokers, and 201 were ever-smokers with COPD. Increased MUC5AC concentrations were more reliably associated with manifestations of COPD than were MUC5B concentrations, including decreased FEV1 and FEF25-75%, and increased prospective exacerbation frequency, RV/TLC, PRM-fSAD, and COPD assessment scores. MUC5AC concentrations were more reactive to cigarette smoke exposure than were MUC5B concentrations. Longitudinal data from 3-year follow-up visits generated a multivariate-adjusted odds ratio for two or more exacerbations of 1·24 (95% CI 1·04-1·47, p=0·015) for individuals with high baseline MUC5AC concentration. Increased MUC5AC, but not MUC5B, concentration at baseline was a significant predictor of FEV1, FEV1/FVC, FEF25-75%, and CAT score decline during the 3-year follow-up. Moreover, current smokers in the at-risk group showed raised MUC5AC concentrations at initial visits and decreased lung function over 3 years. By contrast, former smokers in the at-risk group showed normal MUC5AC concentrations at the initial visit and preserved lung function over 3 years. INTERPRETATION: These data indicate that increased MUC5AC concentration in the airways might contribute to COPD initiation, progression, exacerbation risk, and overall pathogenesis. Compared with MUC5B, greater relative changes in MUC5AC concentrations were observed as a function of COPD severity, and MUC5AC concentration seems to be an objective biomarker to detect disease in at-risk and pre-COPD individuals. These data suggest that MUC5AC-producing pathways could be potential targets for future therapeutic strategies. Thus, MUC5AC could be a novel biomarker for COPD prognosis and for testing the efficacy of therapeutic agents. FUNDING: National Institutes of Health; National Heart, Lung, and Blood Institute.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Radicioni G, Ceppe A, Ford AA, et al. Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2021. PMID: 34058148. doi:10.1016/S2213-2600(21)00079-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。